|1.||Bueno, Raphael: 4 articles (05/2013 - 03/2008)|
|2.||Sugarbaker, David J: 4 articles (03/2012 - 03/2008)|
|3.||Toyooka, Shinichi: 3 articles (06/2011 - 02/2004)|
|4.||Tsukuda, Kazunori: 3 articles (06/2011 - 02/2004)|
|5.||Pass, Harvey I: 3 articles (01/2009 - 02/2002)|
|6.||Jensen, Roderick V: 2 articles (05/2013 - 03/2008)|
|7.||Richards, William G: 2 articles (05/2013 - 03/2008)|
|8.||De Rienzo, Assunta: 2 articles (05/2013 - 03/2008)|
|9.||Chirieac, Lucian R: 2 articles (05/2013 - 03/2008)|
|10.||Date, Hiroshi: 2 articles (04/2013 - 11/2008)|
07/01/2011 - "Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 inactivation, but other highly recurrent mutations have not been described. "
03/28/2011 - "Therefore, we investigated whether malignant pleural mesothelioma (MPMs) histologies were associated with specific patterns of expression of a selected set of genes related to EMT, cell polarity and stemness features. "
11/01/2008 - "We previously reported the results of bacterial artificial chromosome array comprehensive genomic hybridization of malignant pleural mesotheliomas (MPMs), including two cases with high-level amplification in the 11q22 locus. "
11/01/2008 - "We examined the expression and methylation status of BMP3b and BMP6 in malignant pleural mesotheliomas (MPMs). "
02/01/2004 - "We applied this method for 53 cases of primary malignant pleural mesotheliomas (MPMs) and 6 cell lines and found no mutations in these samples. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
|3.||Melanoma (Melanoma, Malignant)
08/01/2013 - "Little is known about survival after a diagnosis of a second or higher-order (multiple) primary melanoma, and no study has explored survival in a population-based sample that included patients with single primary melanomas (SPMs) and multiple primary melanomas (MPMs) of any stage. "
01/01/2016 - "In the majority of primary melanomas in patients with MPMs, BRAF, NRAS, and TERT-promoter genotypes were discordant. "
01/01/2016 - "Up to 8% of melanoma patients present with multiple primary melanomas (MPMs). "
10/01/2015 - "In all, 15,448 patients had a single melanoma and 1122 had MPMs. "
10/01/2015 - "We compared characteristics between patients with MPMs and single primary melanomas and estimated crude and adjusted hazard ratios of MPMs using Cox models. "
09/01/2015 - "Multiple primary malignancies (MPMs) are present when a patient is diagnosed with more than one primary malignancy and when each tumor is histologically unrelated to the others. "
02/20/2015 - "Patients bearing alleles encoding protein with higher functionality were less likely to have a strong family cancer history, whereas those with greater loss of function had MPMs and/or positive family history. "
02/20/2015 - "Correlation with the International Agency for Research on Cancer p53 database further delineated mutational distribution, association with family history, and risk for multiple primary malignancies (MPMs). "
01/01/2015 - "In the general cancer population, one-ninth of patients are at higher risk of developing a second tumor over a lifetime; hence it would be reasonable to conclude that, from a merely theoretical and statistical viewpoint, long-term transplanted patients potentially have a higher risk of developing MPMs. "
06/01/2014 - "We carried out gene expression microarray profiling of 53 surgically resected MPMs tumors along with paired normal tissue. "
01/01/2013 - "In this study, we employed transcriptomics and cytokine arrays to comparatively calculate the responses of murine peritoneal macrophages (MPMs) and human peripheral blood monocytes (HBMs) to leptospiral infection. "
01/01/2013 - "In MPMs and HBMs, the caspase-8 and Fas-associated protein with death domain (FADD)-like apoptosis regulator genes were significantly up-regulated, which supported previous results that the caspase-8 and caspase-3 pathways play an important role in macrophage apoptosis during leptospiral infection. "
|1.||Epidermal Growth Factor Receptor (EGF Receptor)
|2.||Cyclin-Dependent Kinase Inhibitor p16
|6.||Caspase 8 (Caspase-8)
|7.||Caspase 3 (Caspase-3)
|8.||Toll-Like Receptor 4
|9.||Proto-Oncogene Proteins c-akt (Protein Kinase B)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)